Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer
PLoS ONE, Volume 7, No. 12, Article e48993, Year 2012
Notification
URL copied to clipboard!
Description
TP53 and FGFR3 mutations are the most common mutations in bladder cancers. FGFR3 mutations are most frequent in low-grade low-stage tumours, whereas TP53 mutations are most frequent in high-grade high-stage tumours. Several studies have reported FGFR3 and TP53 mutations to be mutually exclusive events, whereas others have reported them to be independent. We carried out a meta-analysis of published findings for FGFR3 and TP53 mutations in bladder cancer (535 tumours, 6 publications) and additional unpublished data for 382 tumours. TP53 and FGFR3 mutations were not independent events for all tumours considered together (OR = 0.25 [0.18-0.37], p = 0.0001) or for pT1 tumours alone (OR = 0.47 [0.28-0.79], p = 0.0009). However, if the analysis was restricted to pTa tumours or to muscle-invasive tumours alone, FGFR3 and TP53 mutations were independent events (OR = 0.56 [0.23-1.36] (p = 0.12) and OR = 0.99 [0.37-2.7] (p = 0.35), respectively). After stratification of the tumours by stage and grade, no dependence was detected in the five tumour groups considered (pTaG1 and pTaG2 together, pTaG3, pT1G2, pT1G3, pT2-4). These differences in findings can be attributed to the putative existence of two different pathways of tumour progression in bladder cancer: the CIS pathway, in which FGFR3 mutations are rare, and the Ta pathway, in which FGFR3 mutations are frequent. TP53 mutations occur at the earliest stage of the CIS pathway, whereas they occur would much later in the Ta pathway, at the T1G3 or muscle-invasive stage. © 2012 Neuzillet et al.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC3521761/bin/pone.0048993.s001.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC3521761/bin/pone.0048993.s002.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC3521761/bin/pone.0048993.s003.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC3521761/bin/pone.0048993.s004.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC3521761/bin/pone.0048993.s005.doc
Authors & Co-Authors
Neuzillet, Yann
France, Versailles
Université de Versailles Saint-quentin-en-yvelines
France, Paris
Institut Curie
France, Paris
Cnrs Centre National de la Recherche Scientifique
Paoletti, Xavier
France, Paris
Cancer et Génome : Bioinformatique, Biostatistiques et Épidémiologie Des Systèmes Complexes
Ouerhani, Slah
France, Paris
Institut Curie
France, Paris
Cnrs Centre National de la Recherche Scientifique
France, Paris
Inserm
Tunisia, Tunis
Université de Tunis el Manar, Faculté Des Sciences de Tunis
Tunisia, Tunis
Institut Pasteur de Tunis
Mongiat-Artus, Pierre
France, Paris
Hôpital Saint-louis
France, Paris
Génomes, Biologie Cellulaire et Thérapeutique
Soliman, Hany R.
France, Paris
Génomes, Biologie Cellulaire et Thérapeutique
France, Paris
Hôpital Saint-louis
de Thȩ, Hugues B.
France, Paris
Hôpital Saint-louis
France, Paris
Cnrs Centre National de la Recherche Scientifique
Sibony, Mathilde
France, Paris
Hôpital Tenon
Denoux, Yves
France, Suresnes
Hopital Foch
Molinié, Vincent
France, Paris
Groupe Hospitalier Paris Saint-joseph
Hérault, Aurélie
France, Paris
Institut Curie
France, Paris
Cnrs Centre National de la Recherche Scientifique
Lepage, May Linda
France, Paris
Institut Curie
France, Paris
Cnrs Centre National de la Recherche Scientifique
Maillé, Pascale
France, Creteil
Hôpital Henri Mondor
Renou, Audrey
France, Creteil
Hôpital Henri Mondor
Vordos, Dimitri
France, Creteil
Hôpital Henri Mondor
Abboü, Clément Claude
France, Paris
Inserm
France, Creteil
Hôpital Henri Mondor
Bakkar, Ashraf A.
Egypt, El-arish
Sinai University
Asselain, B. J.
France, Paris
Cancer et Génome : Bioinformatique, Biostatistiques et Épidémiologie Des Systèmes Complexes
Kourda, Nadia
Tunisia, Tunis
Université de Tunis el Manar, Hôpital Charles Nicolle
El Gaaied, Amel Ben Ammar
Tunisia, Tunis
Université de Tunis el Manar, Faculté Des Sciences de Tunis
Leroy-Viard, Karen
France, Creteil
Hôpital Henri Mondor
Laplanche, Agnès C.
France, Villejuif
Institut de Cancerologie Gustave Roussy
Benhamou, Simone
France, Villejuif
Institut de Cancerologie Gustave Roussy
Lebrét, Thierry
France, Versailles
Université de Versailles Saint-quentin-en-yvelines
Allory, Yves
France, Paris
Inserm
France, Creteil
Hôpital Henri Mondor
Radvanyi, F.
France, Paris
Institut Curie
France, Paris
Cnrs Centre National de la Recherche Scientifique
Statistics
Citations: 45
Authors: 25
Affiliations: 16
Identifiers
Doi:
10.1371/journal.pone.0048993
e-ISSN:
19326203
Research Areas
Cancer
Study Approach
Systematic review